Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Citation record

Study start

2014-07-16

NCT number

NCT02051218

Phase

Phase3

Overall status

Terminated

Study type

Interventional

Lead sponsor

Swiss Cancer Institute

Enrollment

1,380 participants

Conditions

Metastatic Breast Cancer · Metastatic Prostate Cancer · Bone Metastases

Interventions

Denosumab (reduced dosing) (Drug) · Denosumab (standard dosing) (Drug)

Last updated at source

23 Oct 2026

Original source

https://clinicaltrials.gov/study/NCT02051218

This page reproduces citation metadata only. Inclusion in the Avion Science research library does not imply endorsement and does not establish the safety, efficacy or intended use of any Avion Science compound. Refer to the original record for complete study information.